Impact of body mass index on the development of pocket hematoma: A retrospective study in Chinese people

Jian-Ping GUO1, Zhao-Liang SHAN1, Hong-Yang GUO1, Hong-Tao YUAN1, Kun LIN1, Yue-Xiang ZHAO2, Yu-Tang WANG1,2
1Department of Cardiology, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China
2First Department of Cardiology, Nanlou Clinical Division of Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China

Abstract

Background Pocket hematoma is one of the major complications associated with cardiovascular implantable electronic devices (CIEDs) implantation. The aim of this study is to evaluate the impact of body mass index (BMI) on the occurrence of pocket hematoma after CIEDs implantation. Methods The study is a retrospective review of 972 patients receiving CIEDs implantation between 2008 and 2012 in a tertiary hospital. Results Twenty-two patients (2.2%) developed severe pocket hematoma requiring re-intervention. The hematoma rate (4.6%, n = 15) of patients with a BMI of < 23 kg/m² was significantly higher compared with that of patients with a BMI of ≥ 23 kg/m² (1.1%, n = 7, P < 0.001). In multivariate regression analysis, a BMI < 23.0 kg/m² may be associated with the development of severe pocket hematoma. An increase of 1.0 kg/m² in BMI was associated with lower incidence of hematoma formation (OR: 0.84; 95% CI: 0.74-0.95; P = 0.006). Conclusion BMI < 23 kg/m² was associated with a higher incidence of pocket hematoma, requiring re-intervention. The data support that great care must be taken when patients were with a lower BMI received CIEDs implantation.

Keywords: Hematoma; Pacemaker; Body mass index; Complication

1 Introduction

With expanding indications for cardiovascular implantable electronic devices (CIEDs) [bradycardia pacemakers (PMs), implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapeutic devices with pacing only (CRT-P) and defibrillator (CRT-D)], the number of eligible recipients has increased significantly. Pocket hematoma is an infrequent complication associated with the CIED, with an incidence rate ranging from 2% to 5%, [1,2] accounting for 14%–17% of early reoperations. [3,4] Pocket hematoma is associated with localized pain, longer hospital stays, the risk of reoperations and an increased possibility of infection. [2,5]

The effect of antiplatelet and anticoagulation therapy on the formation of pocket hematoma has been widely researched. [2,6,9] Previous studies have shown that complication rates increase with complex devices, including ICDs and CRTs. [7–9] Furthermore, it has also been reported that chronic kidney disease is an independent risk factor for pocket hematoma formation. [10,11] Research studies have also suggested that the patients’ left ventricular function did not affect the formation of pocket hematoma, [2] unlike surgical experience. [2,12] Previous studies have demonstrated that a lower body mass index (BMI) was associated with a higher incidence of pocket hematoma, requiring re-intervention. The aim of this study is to evaluate the impact of BMI on the incidence of pocket hematoma. We conducted a retrospective analysis of patients receiving procedures with CIEDs using data from the Department of Cardiology at the Chinese PLA General Hospital between 2008 and 2012.

2 Methods

2.1 Study population

This study retrospectively reviewed 990 consecutive procedures involving CIEDs at the Department of Cardiol-
ogy, Chinese PLA General Hospital, between 2008 and 2012. Of these, patients who were not followed for three months or died from causes unrelated to their operations within the first three months were excluded, resulting in 972 procedures available for analysis.

2.2 Study protocol

The indications for operations were based on the prevalent international guidelines, with the surgical strategy remaining unchanged during the period of the study. Puncture of the subclavian vein was used under local anesthesia in almost all of the patients except for two cases that received cephalic vein cut down instead. Pacemaker generators were routinely placed subcutaneously with careful hemostasis.

A course of prophylactic antibiotic treatment with either penicillin or a first generation cephalosporin was started 0.5–2 h prior to the implantation until the third day after the procedure. We stopped any unnecessary medication which might be related to severe hematoma, such as aspirin, warfarin, plavix, etc.

Severe pocket hematoma was diagnosed as palpable swelling of the pocket causing pain and prolonged hospitalization (i.e., ≥ 1 day than the scheduled hospital discharge), whether or not accompanied by anticoagulation treatment cease, reoperation, evacuation, or blood transfusion. According to recommendations of “Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies”, the cut-off point (BMI = 23 kg/m²) was chosen as the public health action point for many Asian populations. Therefore, the patients were grouped into two categories according to their baseline BMI value: BMI < 23 kg/m² and ≥ 23 kg/m². Renal insufficiency was defined as a glomerular filtration rate (GFR) < 60 mL/min per 1.73 m². The GFR was calculated using a modification of the diet in renal disease study equation.

All the patients had their wounds assessed daily by a cardiologist or an experienced cardiology trainee. Patients were discharged and followed for three months after the procedure at the implant center. All pocket hematoma cases were treated with aggressive external compression and/or needle drainage. Using this approach, pocket evacuation was only performed in one case.

The researchers retrospectively reviewed the patient files for selected clinical and procedural characteristics that might be related to severe hematoma. The clinical variables included age, gender, BMI, diabetes, hypertension, atrial fibrillation, past history of myocardial infarction, coronary artery disease, renal insufficiency, platelet count, international normalized ratio (INR), heart failure, left ventricular ejection fraction (LVEF), and the use of antiplatelet (aspirin or clopidogrel) or anticoagulation therapy (warfarin or low-molecular weight heparin). The procedural variables also included the type of implant device and the implanters’s level of experience (cardiologist or trainee).

2.3 Statistical analysis

Statistical analysis was performed using SPSS version 10.0 (Chicago, IL, USA). The data were expressed as the mean ± SD. Categorical variables were represented by frequencies, which were compared by χ² test or Fisher’s exact test as appropriate. Univariate and multivariate logistic regressions were done with stepwise procedures to construct a final best fit logistic regression model to determine the predictors in the development of the pocket hematoma. This method specifies the significance level at P ≤ 0.25 for entering and exiting an explanatory variable in the stepwise model. We estimated the ORs and the 95% CIs for different levels of exposure. Potential predictors with P < 0.05 on univariate analysis were included in the multiple regression model using a stepwise approach, and predictors with P < 0.05 in the multivariable model were retained. The final model selection was based on clinical and statistical significance. Log-rank analysis was used to determine the influence of pocket hematoma on hospital stay. P < 0.05 was considered statistically significant.

3 Results

A total of 972 CIEDs procedures (69.7 ± 13.3 years, male 68%) were enrolled in the study. The mean BMI of all the patients was 24.2 ± 3.5 kg/m². Eight hundred and fifty four (87.9%) underwent new implantations, with the remaining 12.0% undergoing replacement. One hundred and twenty eight (13.2%) were on aspirin, fifteen (1.5%) were on clopidogrel and ten (1.0%) were on both. Only three of the patients were on bridging subcutaneous enoxaparin and ten were on therapeutic warfarin therapy. The mean glomerular filtration rate (GFR) of the study population was 82.3 ± 23.2 mL/min per 1.73 m².

Of all the procedures, 584 (60.1%) were performed by a cardiologist and 388 (40.0%) by a trainee. All ICDs and CRT devices were implanted by cardiologists. The hematoma rate in bradycardia pacemaker implantations was 5 out of 452 (1.1%) in procedures performed by cardiologists and 7 out of 388 (1.8%) of implantations carried out by trainees (P > 0.05).

The hematoma rate was 10 out of 132 (7.6%) in ICD and CRT device implantations and 5 out of 452 (1.1%) in bradycardia PM implantation when the devices were implanted by cardiologists (P < 0.01).

In total, 2.2% (n = 22) of the population developed se-
vere pocket hematoma, which was diagnosed at the mean time of 5.5 ± 8.5 days (minimum one days and maximum 43 days) and needed re-intervention. Ninety one percent of hematoma cases (n = 20) developed within the first week of the procedure. No heparin or warfarin was administered to patients with pocket hematoma. Eight (36%) patients with pocket hematoma were on aspirin and three patients were on both aspirin and clopidogrel.

Log-rank analysis revealed that patients with hematoma showed significantly longer post-procedure hospital stays (4.0 ± 4.2 days vs. 17.6 ± 8.4 days, P < 0.001) compared with patients without hematoma. Baseline clinical characteristics, the types of devices used, and the relevant rates of hematoma are listed in Table 1.

Patients were grouped into two categories according to the baseline BMI value: BMI < 23.0 kg/m² (n = 338, 34.8%) and BMI ≥ 23.0 kg/m² (n = 634, 65.2%). Compared with patients in the BMI < 23.0 kg/m² category, patients in the BMI ≥ 23.0 kg/m² category showed a higher prevalence of hypertension, and significantly lower rate of hematoma development (all P < 0.001). No differences in the two categories were present in the age, gender, number of patients afflicted with diabetes, atrial fibrillation, history of myocardial infarction, coronary artery disease, renal insufficiency, platelet count, INR, New York Heart Association (NYHA) heart failure function class and device type. Baseline characteristics by different BMI are shown in Table 2.

Of all the patients, 16.1% (n = 156) were associated with renal insufficiency. Of these patients, 10.2% (n = 16) showed severe hematoma. Among patients undergoing dual antiplatelet therapy with aspirin and clopidogrel, 3 out of 15 (33.3%) of them developed severe hematoma.

In total, 13% (n = 126) of all patients underwent an ICD or CRT procedure, with the remaining 87.0% undergoing bradycardia pacemaker implantation (single or dual-chamber pacemaker). Almost 9% (n = 11) of patients underwent the ICD or CRT procedure and 1.3% (n = 11) of patients were treated with bradycardia PM developed severe pocket hematoma (P < 0.001).

Pocket hematoma added 320 additional hospital treatment days, accounting for a mean extension in hospital stay of 14.5 day/patient. Pocket hematoma was treated with aggressive external compression and/or needle drainage. Using this approach, pocket evacuation was only performed in one case.

The univariate analysis showed that eight predictors were associated with higher incidence of severe pocket hematoma warranting re-intervention (Table 3). After adjusting for confounders, the following factors; BMI < 23.0 kg/m², dual antiplatelet therapy, complex devices, and renal insuf-

### Table 1. Baseline clinical characteristics, including the type of devices patients had in relation to the occurrence of hematoma.

|                          | Total, n = 972 | With hematoma, n = 22 | Without hematoma, n = 950 | P-value |
|--------------------------|---------------|-----------------------|---------------------------|---------|
| Age, yrs                 | 69.7 ± 13.3   | 70.9 ± 9.1            | 69.7 ± 13.4               | 0.560   |
| Male sex, %              | 68.0          | 68.1                  | 68.0                      | 0.990   |
| BMI (%, < 23 kg/m²)      | 34.8          | 68.1                  | 34                        | 0.001   |
| Diabetes, %              | 21.5          | 18.2                  | 21.6                      | 0.700   |
| Hypertension, %          | 58.1          | 36.3                  | 58.6                      | 0.040   |
| Atrial fibrillation, %   | 32.3          | 45.4                  | 32.0                      | 0.180   |
| MI history, %            | 12.3          | 36.4                  | 11.7                      | 0.001   |
| CAD, %                   | 42.6          | 63.6                  | 42.1                      | 0.040   |
| Renal insufficiency, mL/min per 1.73 m² | 82.3 ± 23.2 | 61.5 ± 32.6           | 82.0 ± 23.6               | 0.008   |
| Platelet count (× 10⁹/L) | 164.1 ± 46.5  | 136.7 ± 71.5          | 164.5 ± 47.1              | 0.210   |
| INR                      | 1.1 ± 0.2     | 1.1 ± 0.1             | 1.1 ± 0.2                 | 0.430   |
| Previous heart failure history, % | 19.1      | 72.7                  | 17.9                      | 0.000   |
| LVEF                     | 0.7 ± 3.6     | 0.5 ± 0.2             | 0.7 ± 3.3                 | 0.130   |
| Complex device, %        | 13.6          | 50.0                  | 12.7                      | 0.000   |
| Device replacement, %    | 12.1          | 31.8                  | 11.7                      | 0.004   |
| Post-procedure hospital stay, day | 4.1 ± 4.4 | 17.6 ± 8.4           | 4.0 ± 4.2                 | 0.000   |
| Infection, %             | 0.2           | 4.5                   | 0.1                       | 0.000   |

Data are presented as mean ± SD or percent. Atrial fibrillation is defined as any previous episode of atrial fibrillation; complex device is referred to ICD or CRT-P or CRT-D; renal insufficiency is defined as a glomerular filtration rate < 60 mL/min per 1.73 m². BMI: body mass index; CAD: coronary artery disease; CRT-D: cardiac resynchronization therapy devices with defibrillator; CRT-P: cardiac resynchronization therapy devices with pacing; INR: international normalized ratio; LVEF: left ventricular ejection fraction; MI: myocardial infarction.
Table 2. Baseline characteristic of patients by BMI categories.

|                | BMI < 23 kg/m² (n = 338, 34.8%) | BMI ≥ 23 kg/m² (n = 634, 65.2%) | P-value |
|----------------|----------------------------------|----------------------------------|---------|
| Age, yrs       | 69.2 ± 14.4                      | 70.2 ± 12.4                      | 0.290   |
| Male           | 218 (64.5%)                      | 443 (69.8%)                      | 0.080   |
| BMI            | 20.5 ± 1.9                       | 26.2 ± 2.3                       | <0.001  |
| Diabetes       | 68 (20.1%)                       | 143 (22.6%)                      | 0.600   |
| Hypertension   | 172 (50.9%)                      | 395 (62.3%)                      | <0.001  |
| Atrial fibrillation | 95 (28.0%)              | 196 (30.9%)                      | 0.360   |
| MI history     | 40 (11.8%)                       | 84 (13.2%)                       | 0.530   |
| CAD            | 146 (43.2%)                      | 273 (43.1%)                      | 0.960   |
| Renal insufficiency, mL/min per 1.73m² | 82.6 ± 28.6             | 81.2 ± 19.9                       | 0.420   |
| Platelet count (× 10⁹/L) | 167.6 ± 56.8             | 165.4 ± 45.6                      | 0.470   |
| INR            | 1.1 ± 0.3                        | 1.1 ± 0.1                        | 0.210   |
| No heart failure history | 278 (82.2%)              | 516 (81.4%)                      | 0.740   |
| LVEF           | 0.6 ± 0.1                        | 0.7 ± 3.7                        | 0.290   |
| Complex device | 45 (13.3%)                       | 81 (12.8%)                       | 0.530   |
| Device replacement | 47 (13.9%)              | 75 (11.8%)                       | 0.350   |
| Hematoma       | 15 (4.4%)                        | 7 (1.1%)                         | <0.001  |

Data are presented as mean ± SD or n (%). Atrial fibrillation is defined as any previous episode of atrial fibrillation; complex device is referred to ICD or CRT-P or CRT-D; renal insufficiency is defined as a glomerular filtration rate < 60 mL/min per 1.73 m². BMI: body mass index; CAD: coronary artery disease; CRT-D: cardiac resynchronization therapy devices with defibrillator; CRT-P: cardiac resynchronization therapy devices with pacing; INR: international normalized ratio; LVEF: left ventricular ejection fraction.

Table 3. Univariate analysis of predictors of pocket hematoma formation.

| Predictor                         | OR (95% CI)          | P-value |
|-----------------------------------|----------------------|---------|
| Age                               | 1.01 (0.97–1.03)     | 0.810   |
| Male vs. female                   | 1.10 (0.33–3.70)     | 0.880   |
| Lower BMI (< 23 kg/m²)            | 0.30 (0.14–0.66)     | 0.003   |
| Coronary artery disease           | 2.68 (1.18–6.07)     | 0.020   |
| MI history                        | 5.60 (2.51–12.49)    | 0.001   |
| LVEF                              | 0.99 (0.90–1.10)     | 0.890   |
| Hypertension                      | 0.81 (0.59–1.12)     | 0.209   |
| Renal insufficiency               | 0.97 (0.95–0.982)    | 0.001   |
| Aspirin vs. no aspirin            | 2.73 (0.76–9.81)     | 0.120   |
| Clopidogrel vs. no clopidogrel    | 8.25 (0.93–72.84)    | 0.060   |
| Dual AP therapy                  | 10.38 (2.74–39.29)   | <0.001  |
| Complex device                    | 14.87 (6.47–34.17)   | <0.001  |
| INR                               | 0.85 (0.112–6.48)    | 0.870   |
| Previous heart failure history    | 2.68 (1.98–3.64)     | <0.001  |
| Device replacement                | 2.73 (1.12–6.63)     | 0.027   |
| Diabetes                          | 1.11 (0.44–2.77)     | 0.830   |

Complex device is referred to ICD or CRT-P or CRT-D; renal insufficiency is defined as a glomerular filtration rate < 60 mL/min per 1.73 m². AP: antiplatelet; BMI: body mass index; CRT-D: cardiac resynchronization therapy devices with defibrillator; CRT-P: cardiac resynchronization therapy devices with pacing; INR: international normalized ratio; LVEF: left ventricular ejection fraction.

Table 4. Multivariate analysis of predictors of pocket hematoma formation.

| Predictor                         | Odds ratio (95% CI) | P-value |
|-----------------------------------|---------------------|---------|
| Low BMI (< 23.0 kg/m²)            | 0.32 (0.12–0.84)    | 0.020   |
| Dual AP therapy                   | 18.01 (3.05–103.18) | 0.001   |
| Device replacement                | 1.72 (0.57–5.19)    | 0.340   |
| Renal insufficiency               | 0.98 (0.97–0.99)    | 0.030   |
| Complex device                    | 8.51 (2.58–28.05)   | 0.001   |
| MI history                        | 0.72 (0.19–2.65)    | 0.620   |
| Previous heart failure history    | 1.48 (0.96–2.27)    | 0.070   |

Complex device is referred to ICD or CRT-P or CRT-D; renal insufficiency is defined as a glomerular filtration rate < 60 mL/min per 1.73 m². AP: antiplatelet; BMI: body mass index; CRT-D: cardiac resynchronization therapy devices with defibrillator; CRT-P: cardiac resynchronization therapy devices with pacing; MI: myocardial infarction.
Figure 1. Predictors of pocket hematoma formation. Renal insufficiency is defined as a glomerular filtration rate < 60 mL/min per 1.73 m². BMI: body mass index; MI: myocardial infarction;

## 4 Discussion

Pocket hematoma is one of the major complications related to the CIED procedure.[7,12] A significant increase in CIEDs implantations will result in a corresponding increase in the number of reported complications associated with the procedure. The pocket hematoma is associated with local discomfort, prolonged hospital stays and an increased risk of re-intervention and related risk of infection.

In our study, we observed that dual antiplatelet therapy, complex devices and renal insufficiency are independent predictors of pocket hematoma, which need re-intervention. The study demonstrated that patients with hematoma endured a longer hospital stay and a higher infection rate, compared to patients without hematoma. The above findings are in accordance with the results from previous studies.[5,7–11]

A recent study demonstrated that device replacements are associated with a significant risk of complications.[7] However, this study illustrated that device replacement did not increase hematoma rates compared with patients who received device implantation in the multivariate analysis. This is probably due to the small sample size or the comparatively reduced dosage of antiplatelet or anticoagulation therapy.

BMI is widely used as an estimate of general adiposity. A linear relationship was observed between BMI and body fat mass.[19] A lower BMI is associated with a thin subcutaneous fat layer. Previous studies have shown that a lower BMI was associated with a higher incidence of post-CIED procedure complications.[13–16] Our study demonstrates that a BMI of < 23.0 kg/m² was associated with development of severe hematoma which needs re-intervention. An increase of 1.0 kg/m² in BMI was associated with lower incidence of hematoma formation. The association between a comparatively lower BMI and hematoma formation might be attributed to the thin subcutaneous layer. Similarly a hematoma may lead to more severe tension in patients with a lower BMI. A recent prospective study described obesity (BMI ≥ 30 kg/m²) as a protective factor in the development of pocket hematoma.[5]

Today, most pulse generators are implanted deep inside the adipose tissue and lying on the pectoralis fascia, which obviates dissection of deeper tissues with a shorter operation time. The overall incidence of hematoma with the above approach is approximately 2%–5%. Hypothetically, this is less likely with the submuscular approach in healthy vascularized patients. According to Knepp’s study,[20] almost 40% of the cases involving generator-repositioning are due to hematoma. After repositioning, the generator in the submuscular plane, no hematoma was reported.

Gold, et al.[21] reported that the overall complication rate due to subcutaneous approach was comparable to the submuscular approach. However, patients in the subcutaneous group weighed on an average of 2.8 kg more than those in the submuscular group, and the mean BMI was much higher compared with our study. In patients with a lower BMI, CIEDs placement in the submuscular plane might be an alternative, to reducing the rate of bleeding.

Previous studies have suggested that hematoma is more common when done by an individual with a lesser level of implanting experience.[12] However, this was not in accordance with the findings of this study, probably due to the comparatively reduced use of antiplatelet or/and anticoagulant therapy in our study sample.

There are several limitations associated with this study. First, because of the small number of outcomes and the retrospective nature of the subgroup analysis, we cannot exclude the possibility that the statistical significance is due to the occurrence of a type I error inflation. In addition, our research did not compare the differences in gender. Second, there were fewer patients undergoing antiplatelet or and anticoagulation therapy in this study compared with other research studies involving pocket hematoma. As a result, the incidence rate of pocket hematoma might be underestimated. However, we excluded the influence of oral antiplatelet and anticoagulation therapy when analyzing the effects of BMI. To the best of our knowledge, this study is the first to address the impact of BMI on the development of pocket hematoma.

## 5 Conclusions

Our study demonstrates that a BMI < 23.0 kg/m² was associated with a higher incidence of pocket hematoma, which needs re-intervention after a CIED procedure. The
data support that great care must be taken when patients received CIEDs implantation with a lower BMI.

References

1. Takahashi T, Bhandari AK, Watanuki M, et al. High incidence of device-related and lead-related complications in the dual-chamber implantable cardioverter defibrillator compared with the single-chamber version. Circ J 2002; 66: 746–750.

2. Wiegand UKH, Lejeune D, Boguszewski F, et al. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/anticoagulation therapy. Chest 2004; 126: 1177–1186.

3. Chauhan A, Grace AA, Newell SA, et al. Early complications after dual chamber versus single chamber pacemaker implantation. Pacing Clin Electrophysiol 1994; 17: 2012–2015.

4. Aggarwal RK, Connelly DT, Ray SG, et al. Early complications of permanent pacemaker implantation: no difference between dual and single chamber systems. Br Heart J 1995; 73: 571–575.

5. Cano O, Osca J, Sancho-Tello MJ, et al. Morbidity associated with three different antiplatelet regimens in patients undergoing implantation of cardiac rhythm management devices. Europace 2011; 13: 395–401.

6. Tolosana JM, Berne P, Mont L, et al. Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial. Eur Heart J 2009; 30: 1880–1884.

7. Poole JE, Gleva MJ, Mela T, et al. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation 2010; 122: 1553–1561.

8. Duray GZ, Schmitt J, Cieck-Hartvig S, et al. Complications leading to surgical revision in implantable cardioverter defibrillator patients: comparison of patients with single-chamber, dual-chamber, and biventricular devices. Europace 2009; 11: 297–302.

9. Lee DS, Krahn AD, Healey JS, et al. Evaluation of early complications related to De Novo cardioverter defibrillator implantation insights from the Ontario ICD database. J Am Coll Cardiol 2010; 55: 774–782.

10. Ahmed I, Gertner E, Nelson WB, et al. Chronic kidney disease is an independent predictor of pocket hematoma after pacemaker and defibrillator implantation. J Interv Card Electrophysiol 2010; 29: 203–207.

11. Tompkins C, McLean R, Cheng A, et al. End-stage renal disease predicts complications in pacemaker and ICD implants. J Cardiovasc Electrophysiol 2011; 22: 1099–1104.

12. Pakarinen S, Oikarinen L, Toivenen L. Short-term implantation-related complications of cardiac rhythm management device therapy: a retrospective single-centre 1-year survey. Europace 2010; 12: 103–108.

13. van Eck JW, van Hemel NM, Zutthof P, et al. Incidence and predictors of in-hospital events after first implantation of pacemakers. Europace 2007; 9: 884–889.

14. Mahapatra S, Bybee KA, Bunch TJ, et al. Incidence and predictors of cardiac perforation after permanent pacemaker placement. Heart Rhythm 2005; 2: 907–911.

15. Link MS, Estes NA3rd, Griffin JJ, et al. Complications of dual chamber pacemaker implantation in the elderly. J Interv Card Electrophysiol 1998; 2: 175–179.

16. Kiviniemi MS, Pirnes MA, Eranen HJ, et al. Complications related to permanent pacemaker therapy. Pacing Clin Electrophysiol 1999; 22: 711–720.

17. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 10: 157–163.

18. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1–S266.

19. Pasco JA, Nicholson GC, Brennan SL, et al. Prevalence of Obesity and the Relationship between the Body Mass Index and Body Fat: Cross-Sectional, Population-Based Data. PLoS One 2012; 7: e29580.

20. Knep EK, Chopra K, Zahiri HR, et al. An effective technique for salvage of cardiac-related devices. Eplasty 2012; 12: e8.

21. Gold MR, Peters RW, Johnson JW, et al. Complications associated with pectoral cardioverter-defibrillator implantation: comparison of subcutaneous and submuscular approaches. J Am Coll Cardiol 1996; 28: 1278–1282.